Login
$CATX
$0.94 +$0.01 (1.32%) After hours

$CATX SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Morich Frank, Director

Bought 15,000 shares ($15K)

16 Nov 2026 Form 4: Williamson Robert F Iii, Director

Bought 24,898 shares ($20.9K)

16 Nov 2026 Form 4: Woods Lori A, Director

Bought 23,750 shares ($20K)

13 Nov 2026 Form 4: Puhlmann Markus, Chief Medical Officer

Bought 6,000 shares ($4.98K) · Bought 35,000 shares ($29.6K)

12 Nov 2026 SCHEDULE 13D/A
12 Nov 2026 Form 4: Spoor Johan M., Director

Bought 47,000 shares ($37.9K)

10 Nov 2026 SCHEDULE 13G
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs

06 Nov 2026 8-K: Other Events

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

06 Nov 2026 8-K: Other Events

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

23 Oct 2026 8-K: Other Events

Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

08 Oct 2026 8-K: Other Events

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

01 Oct 2026 8-K: Other Events

Next-Generation Radiopharmaceuticals Redefining Targeted Oncology

23 Sep 2026 SCHEDULE 13D/A
14 Sep 2026 8-K: Other Events

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

08 Sep 2026 8-K: Other Events

Next-Generation Radiopharmaceuticals Redefining Targeted Oncology

08 Sep 2026 Form 4: Lantheus Alpha Therapy, Llc, 10% owner and 1 other

Sold 80,783 shares ($251K) · Sold 167,149 shares ($526K)

04 Sep 2026 Form 4: Lantheus Alpha Therapy, Llc, 10% owner and 1 other

Sold 42,129 shares ($131K)

04 Sep 2026 Form 4: Lantheus Alpha Therapy, Llc, 10% owner

Sold 78,145 shares ($246K) · Sold 35,769 shares ($112K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support